Pharmacokinetics of Moxifloxacin in an Infant With Mycoplasma hominis Meningitis
Year: 2011
Type: article
Study design: Case Report
Abstract: Treatment of Mycoplasma hominis meningitis in infants is limited by a lack of consensus regarding therapy and limited pharmacokinetic data for agents to which M. hominis is susceptible. We report the successful treatment of a premature infant suffering from M. hominis meningitis with doxycycline and moxifloxacin and provide a pharmacokinetic profile of moxifloxacin.
Language: English
Subfield: Pharmacology (medical)
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funders: Pfizer, Bayer HealthCare, U.S. Food and Drug Administration, Agency for Healthcare Research and Quality, U.S. Public Health Service, National Heart, Lung, and Blood Institute, National Institute of Diabetes and Digestive and Kidney Diseases, Eunice Kennedy Shriver National Institute of Child Health and Human Development
Awards: Duke Research Training Program for Pediatricians, Prevention of Invasive Candidiasis: PK, Safety, and Neurodevelopmental Outcomes, G2102029963, PHARMACOKINETICS OF ANTIMICROBIAL AGENTS IN HIGH RISK INFANTS, North Carolina Collaborative PPRU Network, G3531727035, G5139652136, G5241684758, Pharmacokinetics and Pharmacodynamics of Antibiotics in Premature Infants, Antimicrobial pharmacokinetics and outcomes in vulnerable infants, G6273702591, G7011787740, G7177219445, Prevention of Invasive Candidiasis: PK, Safety, and Neurodevelopmental Outcomes, G8252581345, Mentorship of early-career pediatricians in quantitative methods and therapeutics
OpenAlex ID: W1994823611